Viking Therapeutics
VKTX
165 hedge funds and large institutions have $456M invested in Viking Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 60 increasing their positions, 46 reducing their positions, and 29 closing their positions.
63% more call options, than puts
Call options by funds: $29.3M | Put options by funds: $18M
30% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 46
27% more capital invested
Capital invested by funds: $360M → $456M (+$96.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 168 → 165 (-3)
2.08% less ownership
Funds ownership: 65.79% → 63.71% (-2.1%)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.78M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.87M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.48M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.6M |
| 2 |
Citigroup
New York
|
-$7.4M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.71M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$4.77M |
| 5 |
Two Sigma Investments
New York
|
-$2.98M |
VKTX Hedge Fund Activity: Q1 2019 in Review
165 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2019, worth a combined $456M — up 27% from $360M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of VKTX and 26 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 60 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $6.78M. The largest seller was Fidelity Investments, cutting an estimated $16.6M.
- 165 institutional investors held Viking Therapeutics (VKTX) as of Q1 2019, down from 168 in Q4 2018.
- Funds reported $456M of Viking Therapeutics stock for Q1 2019, up 27% quarter-over-quarter.
- 26 funds opened new Viking Therapeutics positions in Q1 2019 and 29 closed out, a net change of -3 holders.
- The largest Viking Therapeutics buyer in Q1 2019 was Rubric Capital Management (New York), an estimated $6.78M added.
- The largest Viking Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $16.6M sold.
Based on aggregated 13F filings for Q1 2019.